Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: LXRX

Lexicon Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for LXRX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.15

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 12:31 UTC.

What Lexicon Pharmaceuticals, Inc. does

Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines, particularly small molecule drugs. The company devotes most of its resources to sotagliflozin, an orally-delivered compound being developed for hypertrophic cardiomyopathy and type 1 diabetes, while also commercializing its FDA-approved drug INPEFA (sotagliflozin) for heart failure and related conditions. The company is also advancing pilavapadin for neuropathic pain and has licensed LX9851 for obesity treatment to Novo Nordisk.

Summarized from Lexicon Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.15
Debt/equity0.29

Revenue, margins & earnings

FY2021: net loss $88M on revenue $298,000$298,000FY2021FY2022: net loss $102M on revenue $139,000$139,000FY2022FY2023: net loss $177M on revenue $1M$1MFY2023FY2024: net loss $200M on revenue $31M$31MFY2024FY2025: net loss $50M on revenue $50M$50MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-04
Most recent filed transactions — June 2026:
  • 2026-06-04DirectorOption exercise89,312—
  • 2026-06-04DirectorRestricted Stock UnitsOption exercise-89,312—
  • 2026-06-04DirectorOption exercise89,312—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Lexicon Pharmaceuticals, Inc. do?

Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines, particularly small molecule drugs.

When did LXRX last file with the SEC?

Lexicon Pharmaceuticals, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-05-07. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 12:31 UTC. This page is also available as JSON at /api/data?ticker=LXRX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for LXRX and 5,000+ tickers.

Create a free account — keep LXRX
For your agent
GET /api/data?ticker=LXRX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt